Industrial robot with controlled flexibility and simulated force for automated assembly
    93.
    发明授权
    Industrial robot with controlled flexibility and simulated force for automated assembly 有权
    具有控制灵活性和模拟力的工业机器人,用于自动组装

    公开(公告)号:US07340323B2

    公开(公告)日:2008-03-04

    申请号:US11653638

    申请日:2007-01-16

    IPC分类号: G05B15/00

    摘要: An industrial robot that uses a simulated force vector to allow a work piece held by the robot end effector to be mated with a work piece whose location and orientation is not precisely known to the robot. When the end effector makes contact with the location and orientation in which the other work piece is held the robot provides a velocity command to minimize the force of the contact and also provides a search pattern in all directions and orientations to cause the end effector to bring the work piece it is holding in contact with the other work piece. The search pattern and the velocity command are continued until the two work pieces mate.

    摘要翻译: 一种工业机器人,其使用模拟的力向量来允许由机器人末端执行器保持的工件与其机器人的位置和取向不是精确地知道的工件配合。 当末端执行器与保持另一工件的位置和方向接触时,机器人提供速度命令以使接触力最小化,并且还在所有方向和方向上提供搜索模式以使端部执行器带动 其工件与其他工件接触。 搜索模式和速度命令一直持续到两个工件交配。

    System and Method for Implementing Multimedia Ring Back Tone Service
    95.
    发明申请
    System and Method for Implementing Multimedia Ring Back Tone Service 有权
    实现多媒体回铃音服务的系统和方法

    公开(公告)号:US20070268359A1

    公开(公告)日:2007-11-22

    申请号:US11626803

    申请日:2007-01-24

    IPC分类号: H04N7/14

    摘要: The present invention discloses a system for implementing multimedia ring back tone service, which includes a communication network, an MRBT platform storing multimedia ring back tones in the communication network and a VIG. The MRBT platform is respectively connected to the Service Switch Center dominating the terminal and an MGW in the communication network through the VIG; when a calling terminal initiates a call through the Service Switch Center, the VIG establishes a communication link from the terminal to the MRBT platform through the MGW and the VIG before the call is put through; and MRBT platform plays multimedia ring back tones for the calling terminal via the established communication link. The present invention also provides a method for implementing multimedia ring back tone service. The system and the method provided in the present invention can implement multimedia ring back tone service in 3G communication networks.

    摘要翻译: 本发明公开了一种用于实现多媒体回铃音业务的系统,包括通信网络,通信网络中存储多媒体回铃音的MRBT平台和VIG。 MRBT平台分别通过VIG连接到主机终端的业务交换中心和通信网络中的MGW; 当主叫终端通过业务交换中心发起呼叫时,VIG通过MGW和VIG建立从终端到MRBT平台的通信链路, 并且MRBT平台通过建立的通信链路为主叫终端播放多媒体回铃音。 本发明还提供一种实现多媒体回铃音业务的方法。 本发明提供的系统和方法可以在3G通信网络中实现多媒体回铃音业务。

    Dry powder inhaler
    96.
    发明申请
    Dry powder inhaler 有权
    干粉吸入器

    公开(公告)号:US20070235029A1

    公开(公告)日:2007-10-11

    申请号:US11399616

    申请日:2006-04-07

    IPC分类号: A61M15/00 A61M16/10

    摘要: A new dry powder inhaler is developed as a pulmonary medicine delivery device for dispersing precise tiny dosages (10 μg-50 mg) of pure carrier-free ultra-fine powdered medicament (

    摘要翻译: 开发了一种新的干粉吸入器作为肺部药物输送装置,用于将精确的微小剂量(10ug-50mg)的纯载体无细胞超细粉末药物(<5m空气动力学粒径)分散到患者的肺中。 粉末从泡罩细胞中抽出,并通过两个气流辅助的出口管分散。 第一气流从其上游侧穿过泡状细胞,以使剂量显着流化,剂量向上流动。 第二个从泡罩细胞的下游提取流化粉末,用于通过剪切力进一步解散和分散药物粉末。 旋转的多剂量泡罩可以容纳多达60个剂量,其预先用纯超细粉末药物预定量。 与目前大多数通常使用一些赋形剂的干粉吸入器相比,它具有较小体积的较高的药物负载能力。 吸入器有效地将空气流中的雾化药物分散到患者肺的深部内部。 据报道,使用该吸入器,细颗粒分数(<4.7μm)达到高达80%。

    Method and apparatus for payload-based flow estimation
    97.
    发明申请
    Method and apparatus for payload-based flow estimation 有权
    基于有效载荷的流量估计的方法和装置

    公开(公告)号:US20070211647A1

    公开(公告)日:2007-09-13

    申请号:US11372898

    申请日:2006-03-10

    IPC分类号: H04L12/28

    CPC分类号: H04L43/0876 H04L43/022

    摘要: The invention includes a method and apparatus for generating a coincidence count table adapted for determining at least one flow statistic. The method includes receiving a plurality of packets comprising a respective plurality of payloads, comparing payloads associated with consecutive ones of the plurality of packets for identifying at least one simple pattern included within the compared payloads of the consecutive ones of the plurality of packets, for each of the consecutive ones of the plurality of packets, if the at least one simple pattern is identified, processing the at least one simple pattern to form a complex pattern, and for each complex pattern, updating a coincidence count associated with the complex pattern, wherein the coincidence counts are adapted for determining at least one flow statistic.

    摘要翻译: 本发明包括一种用于产生适于确定至少一个流统计量的符合计数表的方法和装置。 该方法包括接收包括相应多个有效载荷的多个分组,比较与多个分组中的连续的分组相关联的有效载荷,用于为每个分组中的连续多个分组的比较的有效载荷中包含的至少一个简单模式 如果所述至少一个简单模式被识别,则处理所述至少一个简单模式以形成复杂模式,并且对于每个复杂模式,更新与所述复杂模式相关联的重合计数,其中, 符合计数适用于确定至少一个流量统计量。

    Production of motif-specific and context-independent antibodies using peptide libraries as antigens
    98.
    发明授权
    Production of motif-specific and context-independent antibodies using peptide libraries as antigens 有权
    使用肽文库作为抗原产生基序特异性和上下文相关抗体

    公开(公告)号:US07259022B2

    公开(公告)日:2007-08-21

    申请号:US10014485

    申请日:2001-11-13

    IPC分类号: A61K38/00 C07K16/00

    CPC分类号: C07K16/00 C07K16/44

    摘要: A method is provided for producing motif-specific, context-independent antibodies which recognize a plurality of peptides or proteins within a genome that contain the same motif. The method includes the step of immunizing a host with a degenerate peptide library antigen featuring (i) a fixed target motif containing one or more invariant amino acids including at least one modified amino acid, and (ii) a plurality of degenerate amino adds flanking the motif. Motif-specific, context-independent antibodies produced by the disclosed method are also provided. The method encompasses motifs consisting of a single modified amino acid, as well as short motifs comprising multiple invariant amino acids including one or more modified amino acids, such as all or part of kinase consensus substrate motifs, protein-protein binding motifs, or other cell signaling motifs. Methods of using the antibodies, e.g. for genome-wide profiling, are also provided.

    摘要翻译: 提供了一种用于产生基序特异性上下文无关抗体的方法,其识别含有相同基序的基因组内的多个肽或蛋白质。 该方法包括用简并肽文库抗原免疫宿主的步骤,其特征在于(i)含有一个或多个包含至少一个修饰的氨基酸的不变氨基酸的固定靶基序,和(ii)多个简并氨基酸, 主题。 还提供了通过公开的方法产生的基于特异性的,与环境无关的抗体。 该方法包括由单个修饰的氨基酸组成的基序,以及包含多个不变氨基酸的短基序,包括一个或多个修饰的氨基酸,例如全部或部分激酶共有底物基序,蛋白质 - 蛋白质结合基序或其他细胞 信号图案。 使用抗体的方法,例如 也提供了全基因组图谱。

    Multimerization of HIV-1 Vif protein as a therapeutic target
    100.
    发明授权
    Multimerization of HIV-1 Vif protein as a therapeutic target 有权
    HIV-1 Vif蛋白多聚化作为治疗靶点

    公开(公告)号:US07226741B2

    公开(公告)日:2007-06-05

    申请号:US10688100

    申请日:2003-10-17

    IPC分类号: C12Q1/68

    摘要: One approach to treating individuals infected with HIV-1 is to administer to such individuals compounds that directly interfere with and intervene in the machinery by which HIV-1 replicates itself within human cells. Although the specific role of HIV-1 viral protein Vif in the viral life cycle is not known, the vif gene is essential for the pathogenic replication of lentiviruses in vivo. The present invention relates to a method for treating an individual exposed to or infected with HIV-1. Individuals identified as being exposed to or infected by HIV-1 are administered a therapeutically effective amount of one or more compounds that inhibit or prevent replication of said HIV-1 by interfering with the replicative or other essential functions of HIV-1 viral protein Vif by interactively blocking the multimerization domain of Vif, thereby preventing multimerization of Vif protein, which is important for Vif function in the lentivirus life cycle. In preferred embodiments, the compound or compounds that interactively block the multimerization domain of Vif are Vif antagonists. Pharmaceutical compositions comprising these compounds are also disclosed.

    摘要翻译: 治疗感染HIV-1的个体的一种方法是向这些个体施用直接干扰和干预HIV-1在人细胞内自身复制的机制的化合物。 虽然HIV-1病毒蛋白Vif在病毒生命周期中的具体作用尚不清楚,但vif基因对于体内慢病毒的致病性复制至关重要。 本发明涉及用于治疗暴露于或感染HIV-1的个体的方法。 被鉴定为暴露于HIV-1或感染HIV-1的个体通过干扰HIV-1病毒蛋白Vif的复制或其它基本功能来抑制或阻止所述HIV-1复制的治疗有效量的一种或多种化合物 交互阻断Vif的多聚化结构域,从而阻止Vif蛋白的多聚化,这对于慢病毒生命周期中的Vif功能是重要的。 在优选的实施方案中,交互式阻断Vif的多聚化结构域的化合物是Vif拮抗剂。 还公开了包含这些化合物的药物组合物。